Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre, adaptive, randomized blinded controlled trial of the safety and efficacy of investigational therapeutics for the treatment of COVID-19 in hospitalized adults – version for European Union/United Kingdom sites

Trial Profile

A multicentre, adaptive, randomized blinded controlled trial of the safety and efficacy of investigational therapeutics for the treatment of COVID-19 in hospitalized adults – version for European Union/United Kingdom sites

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Mar 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baricitinib (Primary) ; Remdesivir (Primary)
  • Indications COVID 2019 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms ACTT; ACTT I; ACTT-EU/UK; NIAID-ACTT
  • Most Recent Events

    • 12 Jan 2021 Results (n=19) of a sub-study; serum specimens were obtained from hospitalized adults with COVID-19 randomized to Remdesivir or placebo from this trial assessing antibody and cytokine responses published in the Journal of Infectious Diseases
    • 23 Nov 2020 According to a Montefiore Health System and Albert Einstein College of Medicine media release, Dr. Zingman was the principal investigator at Montefiore and Einstein for the ACTT-1 and ACTT-2 National Institutes of Health trials
    • 22 Oct 2020 Additional mortality data from a post-hoc analysis were published in the New England Journal of Medicine, according to a Gilead Sciences media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top